SARS-CoV-2 variant with higher affinity to ACE2 shows reduced sera neutralization susceptibility

Monique Vogel; Xinyue Chang; Gilles Sousa Augusto; Mona O Mohsen; Daniel E. Speiser; Martin F Bachmann.
Preprint en Inglés | PREPRINT-BIORXIV | ID: ppbiorxiv-433887

Documentos relacionados

  1. Molecular definition of severe acute respiratory syndrome coronavirus 2 receptor-binding domain mutations: Receptor affinity versus neutralization of receptor interaction.
  2. In vitro data suggest that Indian delta variant B.1.617 of SARS-CoV-2 escapes neutralization by both receptor affinity and immune evasion.
  3. Human serum from SARS-CoV-2-vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant.
  4. Exploring the immune evasion of SARS-CoV-2 variant harboring E484K by molecular dynamics simulations.
  5. Antibody evasion by the P.1 strain of SARS-CoV-2.
  6. Covalently Engineered Protein Minibinders with Enhanced Neutralization Efficacy against Escaping SARS-CoV-2 Variants.
  7. Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera.
  8. Binding of human ACE2 and RBD of Omicron enhanced by unique interaction patterns among SARS-CoV-2 variants of concern.
  9. SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape.
  10. Singular Interface Dynamics of the SARS-CoV-2 Delta Variant Explained with Contact Perturbation Analysis.